Pathology of gestational trophoblastic tumors

• Published in: Gynécologie, obstétrique & fertilité Vol. 28; no. 12; p. 913
• Main Authors: Vuong, P N, Guillet, J L, Houissa-Vuong, S, Lhommé, C, Proust, A, Cristalli, B
• Format: Journal Article
• Language: French
• Published: France 01.12.2000
• Subjects: Chorionic Gonadotropin, beta Subunit, Human - blood; Chorionic Gonadotropin, beta Subunit, Human - secretion; Chorionic Gonadotropin, beta Subunit, Human - urine; Chorionic Villi - pathology; Embryo Implantation; Female; Humans; Hydatidiform Mole - pathology; Immunohistochemistry; Necrosis; Placenta - pathology; Pregnancy; Trophoblastic Neoplasms - pathology; Trophoblasts - pathology; Uterine Neoplasms - pathology
• ISSN: 1297-9589

Gestational trophoblastic tumours result from an abnormal proliferation of different types of trophoblasts. The morphological pattern, together with the immunohistochemical aspect, the cytogenetic data and the clinical profile, helps identify each pathological entity. Hydatiform moles represent malformed placentas caused by genetic aberrations of the villous trophoblast. A complete hydatiform mole displays an hydropic degeneration of all the chorionic villi with a more or less marked proliferation of trophoblasts. A partial hydatiform mole is made up of molar vesicles interspersed with normal chorionic villi. In an invasive hydatiform mole or chorioma destruens, molar vesicles penetrate the myometrium giving rise to a mass distorting the uterine wall. A choriocarcinoma is a malignant proliferation of atypical villous trophoblasts without villi formation. Necrosis, haemorrhage, vascular invasion and distant metastases strongly compromise its outcome. A trophoblastic implantation site tumor, clearly less frequent, results from a proliferation of extravillous trophoblasts, particular for their secretion of human placental lactogen hormone (hPL). This tumour, exceptionally malignant, should be differentiated from the exaggerated placental site and its variants. Except for the placental site trophoblastic tumour, and whatever the outcome (benign or malignant), all gestational trophoblastic tumours secrete the beta-subunit of the chorionic gonadotropic hormone (beta-hCG) more or less abundantly. The serum or urinary level of this unit is proportional to the tumour volume and represents a fundamental basis for the follow-up of these tumours. Multidisciplinary care of high-risk cases allows us to cure the disease, and helps the patient recover her reproductive uterine function.